- Home
- PB vs RYTM Comparison
PB vs RYTM Comparison
Compare PB & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PB
- RYTM
- Stock Information
- Founded
- PB 1983
- RYTM 2008
- Country
- PB United States
- RYTM United States
- Employees
- PB N/A
- RYTM N/A
- Industry
- PB Major Banks
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- PB Finance
- RYTM Health Care
- Exchange
- PB Nasdaq
- RYTM Nasdaq
- Market Cap
- PB 6.3B
- RYTM 6.4B
- IPO Year
- PB 1998
- RYTM 2017
- Fundamental
- Price
- PB $67.86
- RYTM $105.80
- Analyst Decision
- PB Buy
- RYTM Strong Buy
- Analyst Count
- PB 17
- RYTM 12
- Target Price
- PB $80.56
- RYTM $117.00
- AVG Volume (30 Days)
- PB 1.1M
- RYTM 727.7K
- Earning Date
- PB 10-29-2025
- RYTM 11-04-2025
- Dividend Yield
- PB 3.40%
- RYTM N/A
- EPS Growth
- PB 19.26
- RYTM N/A
- EPS
- PB 5.60
- RYTM N/A
- Revenue
- PB $1,239,671,000.00
- RYTM $174,334,000.00
- Revenue This Year
- PB $9.28
- RYTM $46.10
- Revenue Next Year
- PB $19.72
- RYTM $63.02
- P/E Ratio
- PB $12.19
- RYTM N/A
- Revenue Growth
- PB 7.88
- RYTM 54.92
- 52 Week Low
- PB $61.07
- RYTM $45.91
- 52 Week High
- PB $86.76
- RYTM $116.00
- Technical
- Relative Strength Index (RSI)
- PB 58.72
- RYTM 55.08
- Support Level
- PB $64.18
- RYTM $98.52
- Resistance Level
- PB $68.90
- RYTM $108.99
- Average True Range (ATR)
- PB 1.42
- RYTM 4.86
- MACD
- PB 0.13
- RYTM 0.21
- Stochastic Oscillator
- PB 77.22
- RYTM 76.90
About PB Prosperity Bancshares Inc.
Prosperity Bancshares Inc provides retail and commercial banking services to individuals and small to midsize businesses. It provides a wide array of financial products and services to businesses and consumers throughout Texas and Oklahoma. The group provides Personal, Business, Mortgage, and Banking Services.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.